SBIR-STTR Award

Rapid Generation Of Human Therapuetic Antibodies Against Influenza
Award last edited on: 10/13/08

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$180,667
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Yosef Refaeli

Company Information

Taiga Biotechnologies Inc

12635 East Montview Boulevard #100
Aurora, CO 80045
   (720) 859-3547
   taigabiotech@taigabiotech.com
   www.taigabiotech.com
Location: Single
Congr. District: 06
County: Adams

Phase I

Contract Number: 1R43AI078563-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2008
Phase I Amount
$180,667
Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from mouse bone marrow stem cells, fetal cord blood and adult bone marrow stem cells. Phase I of this project includes testing existing mouse antibodies against Influenza for their ability to neutralize pathogenic strains of Influenza and adapting this technology to generate human antibodies against Influenza in a mouse model using human adult stem cells. Phase II of the project will involve optimizing large-scale production and testing of human anti-influenza antibodies.

Public Health Relevance:
This project seeks to optimize a novel method to rapidly generate human therapeutic antibodies against the Influenza virus in a mouse model using human adult stem cell lines. Once this method has been validated for Influenza, the long-term goal to benefit public health will be to use this system to generate antibodies for clinical applications in a variety of global health issues including, but not limited to, HIV-1, tuberculosis and malaria.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----